目的 分析芪藶強(qiáng)心膠囊聯(lián)合左西孟旦治療充血性心力衰竭的療效及對(duì)血清腦鈉素N端前體肽（NT-proBNP）、同型半胱氨酸（Hcy）水平的影響。方法 以2014年1月-2016年6月焦作市第五人民醫(yī)院收治的92例充血性心力衰竭患者為研究對(duì)象，根據(jù)隨機(jī)數(shù)字表法分為觀察組和對(duì)照組，每組46例。對(duì)照組患者在常規(guī)治療基礎(chǔ)上加用左西孟旦，觀察組在對(duì)照組治療方案的基礎(chǔ)上加用芪藶強(qiáng)心膠囊。比較兩組的臨床療效、安全性，及治療前后患者心功能和血清NT-proBNP、Hcy水平的變化。結(jié)果 觀察組的總有效率高于對(duì)照組，但兩組間差異無(wú)統(tǒng)計(jì)學(xué)意義。治療結(jié)束后，兩組的左室射血分?jǐn)?shù)（LVEF）、每搏輸出量（SV）均較治療前顯著升高，左室舒張末期內(nèi)徑（LVEDD）較治療前顯著降低，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組的LVEF、SV顯著高于對(duì)照組，LVEDD顯著低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組的血清NT-proBNP、Hcy水平均較治療前顯著降低，組內(nèi)差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且觀察組的血清NT-proBNP、Hcy水平顯著低于對(duì)照組，組間差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組不良反應(yīng)發(fā)生率比較，差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 芪藶強(qiáng)心膠囊聯(lián)合左西孟旦治療充血性心力衰竭療效顯著，可有效改善患者的臨床癥狀、心功能及血清NT-proBNP、Hcy水平，且安全可靠。

Objective To investigate the clinical effect of Levosimendan and Qiliqiangxin Capsule in congestive heart failure and influence in serum levels of NT-proBNP and Hcy. Methods 92 cases of patients with congestive heart failure in our hospital from January 2014 to June 2016 were selected and divided into observation group and control group,46 cases in each group. Patients in the control group were treated with Levosimendan on the basis of conventional treatment, and the observation group were treated with Levosimendan and Qiliqiangxin Capsule. Compared the clinical effect, safety, and the change of serum levels of NT-proBNP and Hcy before and after treatment. Results The total effective rate of observation group were higher than control group, but the difference was no significant. After treatment, the left ventricular ejection fraction (LVEF), stroke volume (SV) in two groups were significantly higher than that before treatment, the left ventricular end diastolic diameter (LVEDD) were significantly lower than before treatment (P<0.05); and the LVEF and SV of the observation group were significantly higher than the control group, LVEDD was significantly lower than the control group (P<0.05). After treatment, serum levels of NT-proBNP and Hcy of two groups were significantly better than before (P<0.05), and the observation group were better than control group (P<0.05). The difference in the adverse reaction rate was no significant. Conclusion The clinical curative effect of Levosimendan and Qiliqiangxin Capsule in congestive heart failure is distinct, which can effectively improve the clinical symptoms of patients, the cardiac function, serum levels of NT-proBNP and Hcy.